Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
  1. Home
  2. Publications
  3. Supplementary Table S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study

Supplementary Table S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study

Authors:
  • FMFunda Meric-Bernstam
    Funda Meric-Bernstam
  • ECEmiliano Calvo
    Emiliano Calvo
  • KLKeun Seok Lee
    Keun Seok Lee
  • Victor Moreno
    Victor Moreno
  • Yeon Hee Park
    Yeon Hee Park
  • SRSun Young Rha
    Sun Young Rha
  • PCPavani Chalasani
    Pavani Chalasani
  • WZWei Zhong
    Wei Zhong
  • LZLi Zhou
    Li Zhou
  • SPSteven Pirie-Shepherd
    Steven Pirie-Shepherd
  • ALAbraham C.F. Leung
    Abraham C.F. Leung
  • GCGiuseppe Curigliano
    Giuseppe Curigliano

Open Access
Publisher website
Google Scholar
  • 27 November 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1535-7163.30733552
Abstract
Supplementary Table S2 shows the PK results
Keywords
  • BIOLOGICAL AGENTS & THERAPIES
  • ANTIBODY-DRUG CONJUGATES
  • BREAST CANCER
  • CLINICAL TRIAL RESULTS
  • PHASE I CLINICAL TRIALS
  • DRUG TARGETS
  • CELL SURFACE RECEPTOR DRUG TARGETS
  • GASTROINTESTINAL CANCERS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.